表柔比星联合多西他赛或紫杉醇治疗乳腺癌的效果分析
Effect of epirubicin combined with docetaxel or paclitaxel in the treatment of breast cancer
武政喜 1鞠敏育 2张志业 1李建峰 1许学明1
作者信息
- 1. 宁夏石嘴山市第一人民医院 普外肿瘤科,宁夏 石嘴山 753200
- 2. 宁夏石嘴山市第一人民医院 检验科,宁夏 石嘴山 753200
- 折叠
摘要
目的 比较表柔比星联合紫杉醇、表柔比星联合多西他赛治疗乳腺癌的疗效及预后.方法 研究组采用表柔比星和紫杉醇治疗,对照组采用表柔比星联合多西他赛治疗.结果 2组乳腺癌患者治疗结束后进行为期5年的随访,研究组5年生存率(86.67%)高于对照组(68.89%),研究组复发率(4.44%)低于对照组(15.56%),差异有统计学意义(P＜0.05).结论 表柔比星联合紫杉醇治疗乳腺癌效果优于表柔比星联合紫杉醇.
Abstract
Objective To compare the efficacy and prognosis of epirubicin combined with paclitaxel and epirubicin combined with docetaxel in the treatment of breast cancer.Methods Patients in the study group were treated with epirubicin and paclitaxel, while the control group was treated with epirubicin plus docetaxel.Results The two groups of breast cancer patients by the end of the treatment were valid for 5 years of follow-up, five year survival rate(86.67%)than the control group(68.89%), the study group the recurrence rate(4.44%)than in the control group(15.56%), the data had significant differences(P<0.05).Conclusion The epirubicin is conducive to breast cancer patients for better disease control effect and prognosis than star, paclitaxel combined with chemotherapy.
关键词
表柔比星/多西他赛/紫杉醇/乳腺癌/疗效/预后Key words
epirubicin/paclitaxel/docetaxel/breast cancer/efficacy/progn引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据